From: Cost-effectiveness of smoking cessation to prevent age-related macular degeneration
Model Variable | Lifetime AMD-related Benefits of Quitting | Cost per QALY gained (assuming a cost per quitter of $1,400) | |
---|---|---|---|
 | QALYs gained | Costs (excluding caregivers) $ | $ |
Slope parameter (Ï„), which is inversely proportional to the rate of decline in the risk of AMD after quitting relative to current-smokers | Â | Â | Â |
   Upper 95% confidence Limit (slower decline) | 1,600 | -774,000 | 391 |
   Lower 95% confidence Limit (faster decline) | 1,623 | -1,426,000 | Dominant |
Higher utilities for reduced visual acuity ¶ | 1,600 | -1,082,000 | 199 |
Ranibizumab treatment of neovascular AMD || | Â | Â | Â |
   Base-case scenario, as in Table 3, but: |  |  |  |
low ranibizumab cost | 1611 | -360,000 | 645 |
50% of neovascular patients treated | 1613 | -732,000 | 414 |
   Sustained-effect scenario, low ranibizumab cost | 1610 | -282,000 | 694 |
   Non-sustained effect scenario, high ranibizumab cost | 1611 | -929,000 | 292 |